Literature DB >> 20710056

GB virus C coinfection in advanced HIV type-1 disease is associated with low CCR5 and CXCR4 surface expression on CD4(+) T-cells.

Carolynne Schwarze-Zander1, Markus Neibecker, Sabrina Othman, Cristina Tural, Bonaventura Clotet, Jason T Blackard, Bernd Kupfer, Guido Luechters, Ray T Chung, Jürgen K Rockstroh, Ulrich Spengler.   

Abstract

BACKGROUND: Coinfection with the flavivirus GB virus C (GBV-C) is frequent in patients suffering from HIV type-1 (HIV-1) infection because of shared routes of transmission. GBV-C coinfection has been proposed to exert a beneficial influence on HIV-1 infection. In vitro studies demonstrated down-regulation of C-C chemokine receptor type 5 (CCR5) as a potential mechanism by which GBV-C modulates HIV-1 disease progression. We therefore studied surface expression of the two major HIV-1 coreceptors, CCR5 and CXC chemokine receptor type 4 (CXCR4), on CD4(+) and CD8(+) T-cells in 128 HIV-1-positive patients stratified with respect to their GBV-C status, immune function and highly active antiretroviral therapy (HAART) status in vivo.
METHODS: GBV-C infection was studied in 128 HIV-1-infected patients by nested reverse transcriptase PCR. Fluorescence-activated cell sorting analysis was used to measure CCR5 and CXCR4 surface expression on CD4(+) and CD8(+) T-cells.
RESULTS: GBV-C RNA replication was detected in 30% (38/128) of patients. In HIV-1-positive patients with advanced immunodeficiency, we found up-regulation of CCR5 surface expression on CD4(+) T-cells; however, in patients with GBV-C coinfection, no up-regulation of CCR5 CD4(+) T-cells was detected. Furthermore, CXCR4 surface expression was reduced in GBV-C-coinfected patients. These findings were independent of HAART status and HIV-1 viral load. HIV-1 coreceptor expression on CD8(+) T-cells was not altered in patients with GBV-C coinfection.
CONCLUSIONS: GBV-C coinfection in HIV-1 disease leads to reduced expression of the two major HIV-1 coreceptors, CCR5 and CXCR4, on CD4(+) T-cells in patients at an advanced stage of immunodeficiency, providing a possible molecular explanation for the clinical benefit of GBV-C coinfection in late-stage HIV-1 disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20710056      PMCID: PMC3210471          DOI: 10.3851/IMP1602

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  17 in total

1.  No influence of GB virus C replication on the prognosis in a cohort of HIV-1-infected patients.

Authors:  Markus Birk; Stefan Lindbäck; Christer Lidman
Journal:  AIDS       Date:  2002-12-06       Impact factor: 4.177

Review 2.  GB virus type C: a beneficial infection?

Authors:  Jack T Stapleton; Carolyn F Williams; Jinhua Xiang
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

3.  An ELISA for detection of antibodies to the E2 protein of GB virus C.

Authors:  B J Dille; T K Surowy; R A Gutierrez; P F Coleman; M F Knigge; R J Carrick; R D Aach; F B Hollinger; C E Stevens; L H Barbosa; G J Nemo; J W Mosley; G J Dawson; I K Mushahwar
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

4.  Prevalence of hepatitis G viremia among healthy subjects, individuals with liver disease, and persons at risk for parenteral transmission.

Authors:  H H Feucht; B Zöllner; S Polywka; B Knödler; M Schröter; H Nolte; R Laufs
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

5.  The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease.

Authors:  H J Alter; Y Nakatsuji; J Melpolder; J Wages; R Wesley; J W Shih; J P Kim
Journal:  N Engl J Med       Date:  1997-03-13       Impact factor: 91.245

6.  CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression.

Authors:  J Reynes; P Portales; M Segondy; V Baillat; P André; O Avinens; M C Picot; J Clot; J F Eliaou; P Corbeau
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

7.  GB virus type C infection modulates T-cell activation independently of HIV-1 viral load.

Authors:  Maria Teresa Maidana-Giret; Tânia M Silva; Mariana M Sauer; Helena Tomiyama; José Eduardo Levi; Katia C Bassichetto; Anna Nishiya; Ricardo S Diaz; Ester C Sabino; Ricardo Palacios; Esper Georges Kallas
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

8.  Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.

Authors:  Jinhua Xiang; Sarah L George; Sabina Wünschmann; Qing Chang; Donna Klinzman; Jack T Stapleton
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Persistent GB virus C infection and survival in HIV-infected men.

Authors:  Carolyn F Williams; Donna Klinzman; Traci E Yamashita; Jinhua Xiang; Philip M Polgreen; Charles Rinaldo; Chenglong Liu; John Phair; Joseph B Margolick; Dietmar Zdunek; Georg Hess; Jack T Stapleton
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

10.  Regulation of CC chemokine receptor 5 in hepatitis G virus infection.

Authors:  Jacob Nattermann; Hans-Dieter Nischalke; Bernd Kupfer; Jürgen Rockstroh; Lothar Hess; Tilman Sauerbruch; Ulrich Spengler
Journal:  AIDS       Date:  2003-07-04       Impact factor: 4.177

View more
  27 in total

1.  Study design may explain discrepancies in GB virus C effects on interferon-γ and interleukin-2 production and CD38 expression in T lymphocytes.

Authors:  Nirjal Bhattarai; Jack T Stapleton
Journal:  Mem Inst Oswaldo Cruz       Date:  2012-06       Impact factor: 2.743

2.  Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Authors:  Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

3.  GB virus C infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected individuals.

Authors:  Jack T Stapleton; Jeffrey A Martinson; Donna Klinzman; Jinhua Xiang; Seema N Desai; Alan Landay
Journal:  AIDS       Date:  2013-07-17       Impact factor: 4.177

Review 4.  A novel T cell evasion mechanism in persistent RNA virus infection.

Authors:  Jack T Stapleton; Jinhua Xiang; James H McLinden; Nirjal Bhattarai; Ernest T Chivero; Donna Klinzman; Thomas M Kaufman; Qing Chang
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

5.  Transmission of GB virus type C via transfusion in a cohort of HIV-infected patients.

Authors:  Farnaz Vahidnia; M Petersen; G Rutherford; M Busch; S Assmann; J T Stapleton; B Custer
Journal:  J Infect Dis       Date:  2012-03-20       Impact factor: 5.226

Review 6.  GBV-C: state of the art and future prospects.

Authors:  Maria Teresa Maidana Giret; Esper Georges Kallas
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

7.  Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.

Authors:  Jinhua Xiang; James H McLinden; Thomas M Kaufman; Emma L Mohr; Nirjal Bhattarai; Qing Chang; Jack T Stapleton
Journal:  Virology       Date:  2012-05-16       Impact factor: 3.616

8.  GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Thomas M Kaufman; Jack T Stapleton
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

9.  Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits human immunodeficiency virus type 1 replication in human CD4⁺ T-cells.

Authors:  James H McLinden; Jack T Stapleton; Donna Klinzman; Krishna K Murthy; Qing Chang; Thomas M Kaufman; Nirjal Bhattarai; Jinhua Xiang
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

10.  GB virus C particles inhibit T cell activation via envelope E2 protein-mediated inhibition of TCR signaling.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Alan L Landay; Ernest T Chivero; Jack T Stapleton
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.